Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Corcept Therapeutics Incorporated - Common Stock (NQ:CORT)

72.57 -0.28 (-0.38%)
Streaming Delayed Price Updated: 2:13 PM EDT, Jul 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Corcept Therapeutics Incorporated - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
Analyst Ratings for Corcept Therapeutics
Via Benzinga
Analyst Expectations for Corcept Therapeutics's Future
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 15, 2023
Via Benzinga
Corcept Therapeutics Return On Capital Employed Overview
  
Via Benzinga
5 Most Cheapest Stocks In The Healthcare Sector: Bio-Techne, Mirati Therapeutics And More
The most oversold stocks in the healthcare sector presents an opportunity to buy into undervalued companies. 
Via Benzinga
Our 7 Top Biotech Stock Picks for 2023
Following the devastation of Covid-19, there’s greater interest toward medical innovations, thus bolstering biotech stock picks for 2023. 
Via InvestorPlace
Corcept Therapeutics's Earnings: A Preview
Corcept Therapeutics (NASDAQ:CORT) is set to give its latest quarterly earnings report on Thursday, 2022-11-03. Here's what investors need to know before the announcement. Analysts estimate that... 
Via Benzinga
These 3 Stocks Are Winning the Bear Market -- Here's How
Picking the right markets to compete in makes surviving bear markets much more manageable for these companies. 
Via The Motley Fool
7 Under-the-Radar Stocks With 100% Upside Potential
If you're looking for under-the-radar stocks in the current market environment, you're likely to find many imposters so tread carefully. 
Via InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For August 1, 2022
Upgrades 
Via Benzinga
Keep Amphastar Pharmaceuticals Stock On Your Watch List Ahead Of Earnings
IBD 50 member Amphastar Pharmaceuticals stock is expected to report on Aug. 9 and is trading approximately 12% below a 42.41 entry. 
Via Investor's Business Daily
Biotech Hasn't Been This Blazing Hot Since Early 2021 — Here Are The Top 5
The group has several commonalities, including strong ratings and promising charts. 
Via Investor's Business Daily
3 Biotech Stocks Outperforming a Bear Market
These biotech stocks are the most attractive from a valuation and growth perspective as they are less impacted by a slowing economy or change in monetary policy. 
Via InvestorPlace
Apellis Pharmaceuticals Stock Scores Relative Strength Rating Upgrade
ApellisPharmaceuticals sees its Relative Strength Rating reach the elite 90-plus level. 
Via Investor's Business Daily
Vir Biotechnology Stock Joins Rank Of Stocks With RS Ratings Over 90
On Monday, Vir Biotechnology stock had its Relative Strength (RS) Rating upgraded to 91 Monday, up from 85 a day earlier. 
Via Investor's Business Daily
Uniqure Stock Sees Healthy Price Gain, Ranks Among Top 8%
Among its other key ratings, Amsterdam-based gene therapy company Uniqure stock also has a 92 Composite Rating. 
Via Investor's Business Daily
Kezar Life Sciences Stock Shows Rising Market Leadership: Earns 81 RS Rating
The Relative Strength (RS) Rating for Kezar Life Sciences stock jumped into a new percentile Friday, with a rise from 78 to 81. 
Via Investor's Business Daily
Apellis Pharmaceuticals Stock Clears Technical Benchmark, Hitting 80-Plus RS Rating
Apellis Pharmaceuticals stock saw its Relative Strength (RS) Rating upgraded to 85 Friday, up from 79 a day earlier. 
Via Investor's Business Daily
Global Blood Therapeutic Stock Sees Relative Strength Rating Rise To 91
Global Blood Therapeutic stock saw a positive improvement to its Relative Strength Rating on Tuesday, rising from 85 to 91. 
Via Investor's Business Daily
Kura Oncology Stock Scores Rising Relative Strength
On Thursday, Kura Oncology stock had its Relative Strength (RS) Rating stock upgraded to 93 from 81 a day earlier. 
Via Investor's Business Daily
Syndax Pharmaceuticals Stock Sees RS Rating Rise To 92
Syndax Pharmaceuticals stock saw a positive improvement to its Relative Strength (RS) Rating on Thursday, with an upgrade from 80 to 92. 
Via Investor's Business Daily
The Daily Biotech Pulse: Pfizer/BioNTech Ink New COVID-19 Vaccine Supply Pact, Sanofi Hit By FDA Clinical Hold, Angion Biomedica Halts Second Kidney Disease Trial
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Corcept Therapeutics Commences Late-Stage Ovarian Cancer Study
Corcept Therapeutics (NASDAQ: CORT) has initiated pivotal Phase 3 clinical trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer. 
Via Benzinga
Amylyx Pharmaceuticals Stock Clears Key Benchmark, Hitting 90-Plus RS Rating
Amylyx Pharmaceuticals stock reached an key technical benchmark, with its Relative Strength Rating climbing to 95, up from 70 the day before. 
Via Investor's Business Daily
Why Corcept's Pill — And Stock — Is Getting Renewed Attention After Abortion Ruling
Corcept makes a Cushing's drug that, by another name, causes medical abortion. 
Via Investor's Business Daily
Corcept Stock Near Buy Point; Strength Rating Jumps To 91
The new 91 RS Rating means that Corcept stock has outperformed 90% of all other stocks over the past year. 
Via Investor's Business Daily
Top Mid-Cap Stocks: Trading Opportunities For Next Week - Sunday, June 19
A security pattern traces the distinct movements of security prices that, once recognized, help traders to make informed trading decisions. Let's look at some mid-cap stock opportunities by analyzing... 
Via Talk Markets
Preview: Corcept Therapeutics's Earnings
Corcept Therapeutics (NASDAQ:CORT) is set to give its latest quarterly earnings report on Thursday, 2022-05-05. Here's what investors need to know before the announcement. Analysts estimate that... 
Via Benzinga
Corcept Therapeutics's Return On Capital Employed Overview
According to Benzinga Pro, during Q4, Corcept Therapeutics (NASDAQ:CORT) earned $32.05 million, a 5.19% increase from the preceding quarter. Corcept Therapeutics also posted a total of $98.82 million... 
Via Benzinga
Recap: Corcept Therapeutics Q4 Earnings
Corcept Therapeutics (NASDAQ:CORT) reported its Q4 earnings results on Tuesday, February 15, 2022 at 04:00 PM. Here's what investors need to know about the announcement. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.